• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纤维外:骨骼肌的肌内膜基质和毛细血管病理学可能会阻碍婴儿期发病庞贝病的输注治疗。

Outside the fiber: Endomysial stromal and capillary pathology in skeletal muscle may impede infusion therapy in infantile-onset Pompe disease.

机构信息

Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA.

Department of Pediatrics and Medical Genetics, Duke University Medical Center, Durham, North Carolina, USA.

出版信息

J Neuropathol Exp Neurol. 2023 Mar 20;82(4):345-362. doi: 10.1093/jnen/nlad012.

DOI:10.1093/jnen/nlad012
PMID:36864705
Abstract

The survival of infantile-onset Pompe disease (IOPD) patients has improved dramatically since the introduction of enzyme replacement therapy (ERT) with a1glucosidase alfa. However, long-term IOPD survivors on ERT demonstrate motor deficits indicating that current therapy cannot completely prevent disease progression in skeletal muscle. We hypothesized that in IOPD, skeletal muscle endomysial stroma and capillaries would show consistent changes that could impede the movement of infused ERT from blood to muscle fibers. We retrospectively examined 9 skeletal muscle biopsies from 6 treated IOPD patients using light and electron microscopy. We found consistent ultrastructural endomysial stromal and capillary changes. The endomysial interstitium was expanded by lysosomal material, glycosomes/glycogen, cellular debris, and organelles, some exocytosed by viable muscle fibers and some released on fiber lysis. Endomysial scavenger cells phagocytosed this material. Mature fibrillary collagen was seen in the endomysium, and both muscle fibers and endomysial capillaries showed basal laminar reduplication and/or expansion. Capillary endothelial cells showed hypertrophy and degeneration, with narrowing of the vascular lumen. Ultrastructurally defined stromal and vascular changes likely constitute obstacles to movement of infused ERT from capillary lumen to muscle fiber sarcolemma, contributing to the incomplete efficacy of infused ERT in skeletal muscle. Our observations can inform approaches to overcoming these barriers to therapy.

摘要

婴儿型庞贝病(IOPD)患者的生存率自使用 a1 葡萄糖苷酶 alfa 进行酶替代疗法(ERT)以来有了显著提高。然而,长期接受 ERT 治疗的 IOPD 幸存者表现出运动功能障碍,这表明目前的治疗方法不能完全阻止骨骼肌疾病的进展。我们假设在 IOPD 中,骨骼肌的肌内膜基质和毛细血管会出现一致的变化,从而阻碍 ERT 从血液向肌肉纤维的输注。我们回顾性地使用光镜和电镜检查了 6 名接受治疗的 IOPD 患者的 9 个骨骼肌活检。我们发现了一致的超微结构肌内膜基质和毛细血管变化。肌内膜间质被溶酶体物质、糖体/糖原、细胞碎片和细胞器扩张,一些由有活力的肌纤维胞吐,一些在纤维溶解时释放。肌内膜吞噬细胞吞噬了这些物质。在肌内膜中可见成熟的纤维状胶原,肌纤维和肌内膜毛细血管均显示基底层的重复和/或扩张。毛细血管内皮细胞表现出肥大和退化,血管腔变窄。超微结构定义的基质和血管变化可能构成了 ERT 从毛细血管腔向肌纤维肌膜输注的运动障碍,导致 ERT 在骨骼肌中的疗效不完全。我们的观察结果可以为克服这些治疗障碍的方法提供信息。

相似文献

1
Outside the fiber: Endomysial stromal and capillary pathology in skeletal muscle may impede infusion therapy in infantile-onset Pompe disease.纤维外:骨骼肌的肌内膜基质和毛细血管病理学可能会阻碍婴儿期发病庞贝病的输注治疗。
J Neuropathol Exp Neurol. 2023 Mar 20;82(4):345-362. doi: 10.1093/jnen/nlad012.
2
Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease.庞贝病酶替代治疗前后病理特征分析。
Lab Invest. 2006 Dec;86(12):1208-20. doi: 10.1038/labinvest.3700484. Epub 2006 Oct 30.
3
Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).短时间到长时间酶替代疗法(ERT)对晚发性庞贝病(LOPD)骨骼肌组织的影响。
Neuropathol Appl Neurobiol. 2018 Aug;44(5):449-462. doi: 10.1111/nan.12414. Epub 2017 Jul 4.
4
Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy.长期酶替代治疗期间婴儿型庞贝病的骨骼肌病理学
Orphanet J Rare Dis. 2013 Jun 20;8:90. doi: 10.1186/1750-1172-8-90.
5
Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.接受阿糖苷酶α治疗的晚发型庞贝病患者的前瞻性探索性肌肉活检、影像学及功能评估:EMBASSY研究
Mol Genet Metab. 2016 Sep;119(1-2):115-23. doi: 10.1016/j.ymgme.2016.05.013. Epub 2016 May 19.
6
Quantification of muscle pathology in infantile Pompe disease.婴儿型庞贝病中肌肉病理学的量化
Neuromuscul Disord. 2017 Feb;27(2):141-152. doi: 10.1016/j.nmd.2016.10.010. Epub 2016 Nov 3.
7
Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy.接受酶替代疗法治疗的意大利婴儿期起病庞贝病队列的长期临床病史。
Orphanet J Rare Dis. 2018 Feb 8;13(1):32. doi: 10.1186/s13023-018-0771-0.
8
Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.替代型阿糖苷酶α方案治疗庞贝病的安全性和有效性
Neuromuscul Disord. 2015 Apr;25(4):321-32. doi: 10.1016/j.nmd.2014.12.004. Epub 2014 Dec 19.
9
Hearing characteristics of infantile-onset Pompe disease after early enzyme-replacement therapy.婴儿期起病庞贝病患者早期酶替代治疗后的听力特征。
Orphanet J Rare Dis. 2021 Aug 5;16(1):348. doi: 10.1186/s13023-021-01817-1.
10
Expert Group Consensus on early diagnosis and management of infantile-onset pompe disease in the Gulf Region.海湾地区婴儿期庞贝病的早期诊断和管理专家组共识。
Orphanet J Rare Dis. 2022 Oct 27;17(1):388. doi: 10.1186/s13023-022-02545-w.